Finance

Lists
Why is MYGN up 3,31%?
Dive Deeper
MYGN:NASDAQ
Myriad Genetics Inc
USD 4,37
+3,31%
(+0,14) 1D
30 Sep., 10:58:48 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MYGN...
Open
USD 4,28
High
USD 4,37
Low
USD 4,22
Mkt. cap
417,99 m
Avg. vol.
1,97 m
Volume
125,01 k
52-wk high
USD 8,59
52-wk low
USD 2,74
EPS
-USD 1,20
Beta
1,68
Shares outstanding
95,65 m
No. of employees
3 k
Open
USD 4,28
High
USD 4,37
Low
USD 4,22
Mkt. cap
417,99 m
Avg. vol.
1,97 m
Volume
125,01 k
52-wk high
USD 8,59
52-wk low
USD 2,74
EPS
-USD 1,20
Beta
1,68
Shares outstanding
95,65 m
No. of employees
3 k
Profile
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity. Wikipedia
About Myriad Genetics Inc
CEOPaul J. Diaz | Paul J. Diaz
Employees2,7 k
Founded1991
HeadquartersSalt Lake City, Utah, Verenigde State van Amerika
Sector-
Websitemyriad.com
Analyst ratings
Based on 8 analysts giving stock ratings to MYGN in the past 3 months
Sell
Buy
0
Hold
5
Sell
3
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for MYGN in the last 3 months.
Highest
Current USD 4,37
USD 4,00 (-8,47%)
Average
USD 3,04 (-30,43%)
Lowest
USD 2,00 (-54,23%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
UBS
Hold
Initiated
USD 3,60
-17,6%
09/08/2026
Doug Schenkel
UBS
Hold
Maintained
USD 3,60
-17,6%
09/09/2026
David Westenberg
Piper Sandler
Sell
Downgraded
USD 2,00
-54,2%
09/01/2026
Unknown Analyst
Jefferies
Sell
Maintained
USD 2,50
-42,8%
08/21/2026
Mason Carrico
Stephens
Hold
Reiterated
USD 3,00
-31,4%
08/18/2026
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
08/03/2026
Michael Ryskin
Bank of America Securities
Sell
Reiterated
USD 3,20
-26,8%
08/03/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
USD 3,00
-31,4%
08/02/2026
Kyle Boucher
TD Cowen
Hold
Reiterated
USD 4,00
-8,5%
07/31/2026
Daniel Brennan
TD Cowen
Hold
Reiterated
USD 4,00
-8,5%
07/31/2026
William Bonello
Craig-Hallum
Buy
Reiterated
USD 10,00
+128,8%
05/06/2026
Lu Li
UBS
Hold
Maintained
USD 6,00
+37,3%
02/25/2026
Last report
30 Jul. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-USD 0,25 / -USD 0,06
-332,68%miss
Revenue / Est. (USD)
190,70 m / 206,03 m
-7,44%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
205,70 m
209,80 m
200,40 m
190,70 m
Cost of goods sold
61,90 m
63,00 m
62,80 m
63,70 m
Cost of revenue
61,90 m
63,00 m
62,80 m
63,70 m
Research and development expenses
28,20 m
25,50 m
27,10 m
25,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
138,90 m
124,30 m
135,80 m
140,90 m
Operating expense
167,10 m
149,80 m
162,90 m
165,90 m
Total operating expenses
229,00 m
212,80 m
225,70 m
229,60 m
Operating income
-23,30 m
-3,00 m
-25,30 m
-38,90 m
Other non operating income
400,00 k
400,00 k
-
-
EBT including unusual items
-26,20 m
-8,90 m
-34,10 m
-42,60 m
EBT excluding unusual items
-26,20 m
-6,20 m
-28,70 m
-42,60 m
Income tax expense
1,20 m
-1,00 m
-
600,00 k
Effective tax rate
-4,58%
11,24%
-
-1,41%
Other operating expenses
-
-
-
-
Net income
-27,40 m
-7,90 m
-34,10 m
-43,20 m
Net profit margin
-13,32%
-3,77%
-17,02%
-22,65%
Earnings per share
-
0,04
-0,09
-0,25
Interest and investment income
500,00 k
800,00 k
700,00 k
400,00 k
Interest expense
-3,80 m
-4,40 m
-4,10 m
-4,10 m
Net interest expenses
-3,30 m
-3,60 m
-3,40 m
-3,70 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,70 m
9,60 m
-12,80 m
-26,40 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme